After a major slowdown, new drug approvals are likely to pick up after the National Pharmaceutical Pricing Authority (NPPA) decided to de-link price approval of new drugs with its internal guidelines, a move seen as a major relief to pharmaceutical companies. To further ease things for firms awaiting approval of prices for new drugs, the NPPA has also decided to do away with the practice of deciding a new price for each applicant of a new drug.
National Pharmaceutical Pricing Authority eases norms for new drug approvals
Date posted: Thursday 21 December 2017